deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT04013854

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions Melanoma Melanoma Stage III
Interventions Ipilimumab nivolumab
Updated 16 times since 2019 Last updated: Nov 5, 2025 Started: Jan 1, 2020 Primary completion: Aug 31, 2026 Completion: Aug 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Melanoma and Melanoma Stage III, this trial is ongoing. The trial is conducted by Abramson Cancer Center at Penn Medicine and has accumulated 16 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Aug 2019 – ~Feb 2020 · 6 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Apr 2022 · 10 months · monthly snapshot~Apr 2022 – ~May 2023 · 13 months · monthly snapshot~May 2023 – ~Oct 2023 · 5 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Dec 2025 · 12 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

16 versions recorded

  1. Dec 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2024 — Dec 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Nov 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 11 earlier versions

  1. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  2. May 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  3. Apr 2022 — May 2023 [monthly]

    Recruiting PHASE2

  4. Jun 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  5. Mar 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  7. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  8. May 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Feb 2020 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE2

  11. Aug 2019 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center at Penn Medicine
Data source: Abramson Cancer Center at Penn Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations